Phase II Clinical Trial for Treatment of Mild Alzheimer’s Disease
U.S. Study Participants Aged 60 to 85 with Mild Dementia Needed TEL AVIV, March 7, 2017 /PRNewswire/ – Neurim Pharmaceuticals Ltd. announced today that they are seeking up to 500 U.S. patients with mild Alzheimer’s Disease for the start of a Phase II Clinical trial of a ne
Read More0 Comment
© 2024| The NeuroCognitive & Behavioral Institute | Alzheimer's, ADHD, Autism, Multiple Sclerosis, Stroke, Brain Injury Research and Treatment, Anxiety Research, Sleep Study and Treatment, Neuromodulation, Brain mapping | New Jersey | www.neuroci.com
